Peptinovo Biopharma key facts
as of Oct 2026- Operator of a drug delivery company intended to improve cancer survival.
- Peptinovo Biopharma is valued at approximately $23.3M as of Oct 2026, set at its later-stage round, Dec 2024; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $1.3M across 2 recorded rounds; the latest was Seed Round ($1.3M) in Sep 2024.
- Notable investors include Keiretsu Forum, Invest Detroit Ventures, Michigan Economic Development, Alligator Bioscience, Biosciences Research and Commercialization Center — 9 tracked in total.
- Peptinovo Biopharma has filed 3 Form Ds with the SEC since 2021, most recently Dec 2024 ($1.3M sold to 12 investors).
- Status: Privately Held (backing).
Valued at $23.3M at its later-stage round, Dec 2024. Nothing has traded since.
- ·Watch Peptinovo Biopharma: the Monday email on marks, rounds and moves
Peptinovo Biopharma funding rounds
2 roundsPeptinovo Biopharma valuation
Peptinovo Biopharma was valued at $23.3 million at its later-stage round in Dec 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Peptinovo Biopharma raised?
Peptinovo Biopharma has raised $1.3 million across 2 recorded rounds since 2021. The largest was a $955,000 seed round in Jun 2021; the most recent was a $1.3 million seed round in Sep 2024.
Peptinovo Biopharma has filed 3 Form Ds with the SEC since 2021, most recently in Dec 2024 ($1.3 million sold to 12 investors).
Peptinovo Biopharma investors
9 investors are on record for Peptinovo Biopharma, including Keiretsu Forum, Invest Detroit Ventures, Michigan Economic Development and Alligator Bioscience. The seed round in Sep 2024 drew 12 investors.
About Peptinovo Biopharma
Operator of a drug delivery company intended to improve cancer survival. The company helps in the discovery and development of chemotherapy drugs that have resulted in novel nanoparticle technology that safely carries stronger doses of proven drugs directly into cancer cells while keeping them away from healthy tissue, enabling patients with an increase in drug efficacy, decrease in toxicity, and improvement in cancer survival.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2018
- Employees
- 10
- Website
- peptinovo.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.